<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00704561</url>
  </required_header>
  <id_info>
    <org_study_id>457/2008</org_study_id>
    <nct_id>NCT00704561</nct_id>
  </id_info>
  <brief_title>Six-month Coverage and Vessel Wall Response of the Zotarolimus Drug-eluting Stent Implanted in AMI Assessed by Optical Coherence Tomography</brief_title>
  <acronym>OCTAMI</acronym>
  <official_title>Prospective, Randomized, Controlled Arm Study Comparing the Coverage of the Zotarolimus-eluting Stent vs Bare Metal Stent Implanted in ST- Elevation Myocardial Infarction (STEMI).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A.O. Ospedale Papa Giovanni XXIII</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>A.O. Ospedale Papa Giovanni XXIII</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the completeness of struts coverage and vessel
      wall response (strut malapposition, neointima disomogeneities in texture) to the ENDEAVOR
      drug-eluting stent vs the DRIVER stent (bare metal stent of identical metallic platform)
      implanted for the treatment of the culprit lesion in ST-elevation acute myocardial infarction
      (STEMI). To investigate the completeness of the coverage as well as the number of uncovered
      stent struts per section (embedded, uncovered, malapposed) and the neointima texture, high
      resolution (~ 10-15 µm axial) intracoronary optical coherence tomography (OCT)will be used.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major concerns have been raised with regard to the safety of drug-eluting stents (DES) in
      patients with ST-elevation acute myocardial infarction (STEMI). Data from registry studies
      have suggested that implantation of DES during primary PCI could be associated with an
      increased risk for stent thrombosis, probably due to delayed arterial healing. Unlike first
      generation DES, zotarolimus-eluting stents seems to be associated with complete and uniform
      neointimal coverage. The objective of this prospective study is to measure the completeness
      of strut coverage and vessel wall response to the ENDEAVOR zotarolimus-eluting stent vs the
      DRIVER stent (bare metal stent of identical metallic platform) implanted in STEMI patients.
      Optical Coherence Tomography (OCT) that detects smaller degrees of stent strut coverage more
      accurately than IVUS will be used at 6 months follow-up. Intravascular ultrasound (IVUS) will
      be performed as per normal practice at any index procedures and at 6 months follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non inferiority OCT Number of uncovered Stent struts for Endeavor drug eluting stent vs Driver BMSbare metal stent</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of well apposed stent struts without neointima</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of malapposed stent struts without neointima</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of sections with &gt; 30% uncovered struts/total struts</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of sections with incomplete strut apposition</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated MACE(Death, re-MI, TLR) rate at 30 days and 6 months (non inferiority)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In segment OCT neontimal volume</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>DES</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zotarolimus drug-eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bare metal stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ENDEAVOR® drug-eluting stent (Medtronic, Santa Rosa, CA)</intervention_name>
    <description>ENDEAVOR® drug-eluting stent implanted in acute myocardial infarction</description>
    <arm_group_label>DES</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DRIVER bare metal stent (Medtronic, Santa Rosa, Ca)</intervention_name>
    <description>DRIVER bare metal stent implanted in acute myocardial infarction</description>
    <arm_group_label>BMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coronary stent implantation</intervention_name>
    <description>Comparison of Drug Eluting versus Bare Metal Stent</description>
    <arm_group_label>DES</arm_group_label>
    <other_name>Zotarolimus Eluting Coronary Stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bare Metal Coronary Stent</intervention_name>
    <description>Comaprison between Drug Eluting and Bare Metal Coronary Stents</description>
    <arm_group_label>BMS</arm_group_label>
    <other_name>Driver Coronary Stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute Myocardial MI with ST segment Elevation, within 12 hours from symptoms onset

          -  Native coronary artery disease with &gt;70% diameter stenosis (no prior stent implant, no
             prior brachytherapy)

          -  Vessel size in between 2.5 and 3.75 mm

          -  Signed patient informed consent

        Exclusion Criteria:

          -  Lesions in coronary artery bypass grafts

          -  Significant left main disease

          -  Killip class IV

          -  Reecent major bleeding (6 months)

          -  Renal failure with creatinine value &gt; 2.5 mg/dl

          -  Allergy to aspirin and or clopidogrel/ticlopidine

          -  Patient in anticoagulant therapy

          -  IMA due to a stent thrombosis

          -  No suitable anatomy for OCT scan: (only ostial location, very tortuous anatomy, very
             distal or large vessels [≥ 3.75 mm in diameter])
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giulio Guagliumi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Department Ospedali Riuniti di Bergamo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007 Feb 27;115(8):1051-8. Review.</citation>
    <PMID>17325255</PMID>
  </reference>
  <reference>
    <citation>Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Jüni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007 Feb 24;369(9562):667-78.</citation>
    <PMID>17321312</PMID>
  </reference>
  <reference>
    <citation>Kindermann M, Adam O, Werner N, Böhm M. Clinical Trial Updates and Hotline Sessions presented at the European Society of Cardiology Congress 2007: (FINESSE, CARESS, OASIS 5, PRAGUE-8, OPTIMIST, GRACE, STEEPLE, SCAAR, STRATEGY, DANAMI-2, ExTRACT-TIMI-25, ISAR-REACT 2, ACUITY, ALOFT, 3CPO, PROSPECT, EVEREST, COACH, BENEFiT, MERLIN-TIMI 36, SEARCH-MI, ADVANCE, WENBIT, EUROASPIRE I-III, ARISE, getABI, RIO). Clin Res Cardiol. 2007 Nov;96(11):767-86. Epub 2007 Oct 25.</citation>
    <PMID>17955157</PMID>
  </reference>
  <reference>
    <citation>Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, Di Lorenzo E, Kaiser C, Tierala I, Mehilli J, Seyfarth M, Varenne O, Dirksen MT, Percoco G, Varricchio A, Pittl U, Syvänne M, Suttorp MJ, Violini R, Schömig A. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J. 2007 Nov;28(22):2706-13. Epub 2007 Sep 27. Review.</citation>
    <PMID>17901079</PMID>
  </reference>
  <reference>
    <citation>Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006 Jul 4;48(1):193-202. Epub 2006 May 5.</citation>
    <PMID>16814667</PMID>
  </reference>
  <reference>
    <citation>Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol. 2007 Oct 22;100(8B):36M-44M. Review.</citation>
    <PMID>17950831</PMID>
  </reference>
  <reference>
    <citation>Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Münzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE; ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006 Aug 22;114(8):798-806. Epub 2006 Aug 14.</citation>
    <PMID>16908773</PMID>
  </reference>
  <reference>
    <citation>Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, Sawada T, Paredes OL, Hirata K, Yokoyama M. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography. Eur Heart J. 2007 Apr;28(8):961-7. Epub 2006 Nov 29.</citation>
    <PMID>17135281</PMID>
  </reference>
  <reference>
    <citation>Yamaguchi T, Terashima M, Akasaka T, Hayashi T, Mizuno K, Muramatsu T, Nakamura M, Nakamura S, Saito S, Takano M, Takayama T, Yoshikawa J, Suzuki T. Safety and feasibility of an intravascular optical coherence tomography image wire system in the clinical setting. Am J Cardiol. 2008 Mar 1;101(5):562-7. doi: 10.1016/j.amjcard.2007.09.116. Epub 2008 Jan 10.</citation>
    <PMID>18307999</PMID>
  </reference>
  <reference>
    <citation>Pinto Slottow TL, Waksman R. Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on the endeavor zotarolimus-eluting coronary stent. Circulation. 2008 Mar 25;117(12):1603-8. doi: 10.1161/CIRCULATIONAHA.107.752261.</citation>
    <PMID>18362244</PMID>
  </reference>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2008</study_first_submitted>
  <study_first_submitted_qc>June 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2008</study_first_posted>
  <last_update_submitted>February 9, 2010</last_update_submitted>
  <last_update_submitted_qc>February 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Giulio Guagliumi</name_title>
    <organization>Ospedali Riuniti di Bergamo</organization>
  </responsible_party>
  <keyword>Acute Myocardial Infarction</keyword>
  <keyword>Percutaneous Coronary Interventions</keyword>
  <keyword>Optical Coherence Tomography</keyword>
  <keyword>Thrombus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

